The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke "EGRABIS1"

Recruiting

Phase 2 Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients ≥ 18 years with newly symptoms of stroke
- Able to receive exenatide/placebo within 21 days after onset of symptoms
- Radiological confirmed diagnoses of ischemic stroke
- NIHSS between 1-20 at the onset of symptoms
- modified rankin scale (mRS) ≤ 2 prior to onset of symptoms
- Has given written informed consent

Exclusion Criteria

- Intracerebral haemorrhage
- Subdural / epidural hemorrhage
- Subarachnoid haemorrhage
- Previously major structural damage to the brain
- Diabetes type 1
- Diabetes type 2
- Known atrial fibrillation
- > 50% stenosis of internal carotid
- Known allergy to GLP-1 receptor agonists
- Hepatic impairment (ALT> 3 x upper normal limit)
- Renal impairment (eGFR <30 ml / min)
- Inflammatory bowel disease
- Previous pancreatitis
- Heart failure (NYHA class 3-4)
- Pregnancy or lactation
- Patient unable to co-operate to the investigation procedures
- Visualization of the middle cerebral artery bilaterally by transcranial dopple not possible